Oncogenic activation of tyrosine kinases
References (94)
- et al.
Growth Factor Signaling by Receptor Tyrosine Kinases
Neuron
(1992) - et al.
Increased Oncogenic Potential of ErbB is Associated with the Loss of a COOH-terminal Domain Serine Phosphorylation Site
J Biol Cbem
(1992) - et al.
Mechanism of Activation of the Human trk Oncogene
Mol Cell Biol
(1989) - et al.
PTC is a Novel Rearranged Form of the ref Proto-Oncogene and is Frequently Detected in Vivo in Human Thyroid Papillary Carcinomas
Cell
(1990) - et al.
Activation of the ref-11 Oncogene without a Sequence Encoding a Transmembrane Domain and Transforming Activity of Two ref-II Oncogene Products Differing in CarboxyTermini Due to Alternative Splicing
Oncogene
(1989) - et al.
The Cell Cycle and c-Src
Curr Opin Genet Dev
(1993) - et al.
Functional Analysis of the SH2 and SH3 Domains of the lck Tyrosine Protein Kinase
Oncogene
(1992) - et al.
Deletion of the SH3 Domain of Src Interferes with Regulation by the Phosphoryryated Carboxyl-Terminal Tyrosine
J Biol Chem
(1993) - et al.
Identification of a Human src Homology 2-Containing Protein-Tyrosine-Phosphatase: A Putative Homolog of Drosophila Corkscrew
- et al.
c-Abl Has a Sequence-Specific Enhancer Binding Activity
Cell
(1992)
Mutation of a Phenylalanine Conserved in SH3-Containing Tyrosine Kinascs Activates the Transforming Ability of c-Abl
Oncogene
(1993)
Identification of a Protein that Binds to the SH3 Region of Abl and is Similar to Bcr and GAP-rho
Science
(1992)
Nonreccptor Tyrosine Protein Kinases
Oncogene
(1993)
Growth Factors and Cancer
Science
(1991)
Tumorigenicity of the met Proto-Oncogene and the Gene for Hepatocyte Growth Factor
Mol Cell Biol
(1992)
Cell Transformation by the Epidermal Growth Factor Receptor and v-erbB
Cancer Cells
(1991)
Tissue-Specific Transformation by Epidermal Growth Factor Receptor. a Single Point Mutation within the ATP Binding Pocket of the erbB Product Increases its Intrinsic Kinasc Activity and Activates its Sarcomagenic Potential
Dissecting the Activating Mutations in v-erbB of Avian Erythroblastosis Virus Strain R
Virology
(1991)
Muational Analysis of the Role of the Carboxy-Terminal Region of the v-erbB Protein in Erythroid Cell Transformation
Oncogene
(1993)
Characterization of an Angiosarcoma-Inducing Mutation in the erbB Oncogene
Oncogene
(1992)
Molecular and Biochemical Bases for Activation of the Transforming Potential of the Proto-Oncogene c-ros
J Virology
(1993)
Transforming Activities of Human CSF-I Receptors with Different Point Mutations at Codon 301 in their Extracellular Domains
Oncogene
(1990)
Random Mutagenesis of CSF-1 Receptor (FMS) Reveals Multiple Sites for Activating Mutations within the Extracellular Domain
EMBO J
(1992)
Epidermal Growth Factor Receptor Cytoplasmic Domain Mutations Trigger Lignad-Independent Transformation
Mol Cell Biol
(1990)
A Single Amino Acid Substitution is Sufficient to Modify the Mitogenic Properties of the Epidermal Growth Factor Receptor to Resemble that of gp185erbB-2
EMBO J
(1992)
A Point Mutation in the neu Oncogene Mimics Ligand Induction of Receptor Aggregation
Nature
(1989)
Oncogenic Activation of the neu-Encoded Receptor, by a Point Mutation and Deletion
EMBO J
(1988)
An Oncogenic Point Mutation Confers High Affinity Lig and Binding to the neu Receptor
J Biol Cbem
(1993)
Substitution of the erbB-2 Oncoprotein Transmembrane Domain Activates the Insulin Receptor and Modulates the Action of Insulin and Insulin-Receptor Substrate 1
Substitution of the Insulin Receptor Transmembrane Domain with the c-neu/erbB2 Transmembrane Domain Constitutively Ac tivates the Insulin Receptor Kinase in Who
J Biol Chem
(1992)
A Human Oncogene Formed by the Fusion of Truncated Tropomyosin and Protein Tyrosine Kinase Sequences
Nature
(1986)
Mechanism of met Oncogene Activation
Cell
(1986)
Activation of a Novel Human Transforming Gene, ret, by DNA Rearrangement
Cell
(1985)
Detection of Phosphorylated retTPC Oncogene Product in Cytoplasm
Oncogene
(1992)
Dimerization Mediated by a Leucinc Zipper Oncogenically Activates the met Receptor Tyrosine Kinase
Mol Cell Biol
(1993)
Trk-tl is a Novel Oncogene Formed by the Fusion of tpr and trk Genes in a Human Papillary Thyroid Carcinoma
Oncogene
(1992)
Activation of the Receptor Kinase Domain of the trk Oncogene by Recombination with Two Different Cellular Sequences
EMBO J
(1988)
Molecular Characterization of a Thyroid Tumor-Specific Transforming Sequence Formed by the Fusion of ret Tyrosine Kinase and the Regulatory Subunit Rla of Cyclic AMP-dependent Protein Kinase A
Mol Ceil Biol
(1993)
Identification of the Product of Two Oncogenis Rearranged Forms of the RET Proto-Oncogene in Papillary Thyroid Carcinomas
Oncogene
(1992)
Post-Translational Modifications of the env-sea Oncogene Product: the Role of Proteolytic Processing in Transformation
Oncogene
(1993)
Transient Reversion of ras Oncogene-Induced Cell Transformation by Antibodies Specific for Amino Acid 12 of ras Protein
Nature
(1985)
Cytogenic and Molecular Genetic Characterization of Papil iary Thyroid Carcinomas
Genes Chromosomes Cancer
(1992)
Characterization of an Inversion on the Long Arm of Chromosome 10 Juxtaposing DIOS170 and REf and Creating the Oncogenic Sequence REt/PTC
Genetics of src: Structure and Functional Organization of a Protein Tyrosine Kinase
Curr Top Microbiol Immunol
(1989)
SH2 and SH3 Domains: Elements that Control Interactions of Cytoplasmic Signaling Proteins
Science
(1991)
Binding of Transforming Protein, P47gag-crk, to a Broad Range of Phosphotyrosine-Containing Proteins
Science
(1990)
The When and How of Src Regulation
Cell
(1993)
Cited by (123)
(-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase
2008, Journal of Biological ChemistryCitation Excerpt :Tyrosine kinases include the largest group of oncoproteins (47). The recent development of a series of relatively specific protein-tyrosine kinase (PTK) inhibitors with the ability to suppress the proliferation of tumor cells expressing the target PTK in vivo shows that inhibition of deregulated, dominant oncogenic PTKs is often enough to slow tumor progression (48). Research results suggest that targeted molecular cancer therapies can potentially deliver treatment directly to a specific protein or gene target and optimize efficacy and thus reduce adverse side effects often associated with traditional chemotherapy.
MAP-quest: Could we produce constitutively active variants of MAP kinases?
2006, Molecular and Cellular EndocrinologyAtomic resolution structures of the c-Src SH3 domain in complex with two high-affinity peptides from classes i and II
2013, Acta Crystallographica Section D: Biological CrystallographyGlycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review
2024, Frontiers in PharmacologyReceptor tyrosine kinase (c-Kit) inhibitors: A potential therapeutic target in cancer cells
2016, Drug Design, Development and Therapy
- ∗
present address, Dept of Pharmacology, New York University Medical Center, 550 First Avenue, New York, New York 10016, cyUSA.
Copyright © 1994 Published by Elsevier Ltd.